论文部分内容阅读
目的探讨大肠癌中多药耐药基因ＭＤＲ１与ｐ５３表达之间的关系。方法利用免疫组化研究６０例大肠癌及２０例大肠腺瘤ＭＤＲ－１，ｐ５３的表达。结果显示６０例大肠癌切片中ＭＤＲ－１与ｐ５３的阳性表达率为５７％和３７％，１０例正常大肠组织和２０例大肠腺瘤仅２０％显示ＭＤＲ－１阳性表达，ｐ５３在正常大肠组织，管状腺瘤中全部阴性，仅一例有不典型增生的绒毛状腺瘤为阳性表达。同时显示ｐ５３在不同分化的大肠癌中与ＭＤＲ表达呈正相关。结论１）通过检测ＤＭＲ－１可以对大肠癌病人进行化疗敏感性预测。２）ｐ５３过度表达对ＭＤＲ－１基因可能具有诱导和增加效应。３）ｐ５３和ＭＤＲ－１一起可用作判断病人预后，生物学行为的一个有用参数。
Objective To investigate the relationship between multidrug resistance gene MDR1 and p53 expression in colorectal cancer. Methods Immunohistochemistry was used to study the expression of MDR-1 and p53 in 60 colorectal cancers and 20 colorectal adenomas. The results showed that the positive rate of MDR-1 and p53 in 60 cases of colorectal cancer was 57% and 37%. Only 10% of normal colorectal tissue and 20 cases of colorectal adenoma demonstrated MDR-1 positive expression. p53 was in normal colorectal tissue. All tubular adenomas were negative. Only one case of atypical hyperplasia villous adenoma was positive. It was also shown that p53 was positively correlated with MDR expression in differently differentiated colorectal cancers. Conclusion 1) The detection of DMR-1 can predict the sensitivity of chemotherapy for patients with colorectal cancer. 2) p53 overexpression may have induced and increased effects on the MDR-1 gene. 3) Together with MDR-1, p53 can be used as a useful parameter to determine the prognosis and biological behavior of patients.